June 24, 2021
June 24, 2021 – Elevation Oncology, Inc. (NASDAQ: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares were offered by Elevation Oncology. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Elevation Oncology, were $115 million. The shares began trading on the Nasdaq Global Select Market on June 25, 2021 under the ticker symbol “ELEV.” FLG partner Eric Hall assisted.
Recent News
Cap Hill Brands Merges with Juvo+ to form Infinite Commerce
March 8, 2024 (Geekwire.com) – Seattle-based Cap Hill Brands, which raised more than $250 million to acquire and grow e-commerce shops, has merged with Juvo+, a company that focuses on developing and selling its own products online. Terms of the all-stock deal were not disclosed. The combined company is now…Read More
Read More
